Immunization and Vaccination Recommendations for Older Adults

Vaccine schedules shift meaningfully at age 65 — not because the diseases change, but because the immune system does. This page covers which vaccines the Advisory Committee on Immunization Practices (ACIP) recommends for adults 65 and older, how those recommendations work in practice, and how to think through timing decisions when managing chronic conditions or coordinating care across providers.

Definition and scope

The immune system's response to pathogens weakens with age — a process called immunosenescence. Antibody production slows, T-cell repertoire narrows, and the inflammatory response becomes less precise. The practical consequence: older adults face higher rates of severe illness and death from infections that younger adults shake off in a week.

ACIP, which operates under the Centers for Disease Control and Prevention, publishes an annual adult immunization schedule that addresses this directly. The 2024 schedule (CDC Adult Immunization Schedule) identifies five core vaccine categories specifically recommended or dose-adjusted for adults 65 and older:

1. Influenza — one dose annually, with high-dose or adjuvanted formulations preferred over standard formulations for adults 65+
2. COVID-19 — updated annually, with at least one dose of the most current formulation recommended per season
3. Pneumococcal — PCV20 alone, or PCV15 followed by PPSV23, depending on prior vaccination history
4. Shingles (Recombinant Zoster Vaccine, RZV) — two doses, 2 to 6 months apart, for all immunocompetent adults 50 and older
5. Tdap or Td — Tdap once if not previously received, then Td booster every 10 years

The scope extends beyond these five for adults with specific medical conditions — asplenia, chronic kidney disease, diabetes, or immunocompromising conditions each trigger additional recommendations for vaccines like Hib, MenACWY, MenB, and Hepatitis B.

How it works

Vaccine protection in older adults operates differently than in younger populations, and understanding the mechanism matters for setting realistic expectations.

High-dose influenza vaccine (Fluzone High-Dose Quadrivalent, manufactured by Sanofi) contains four times the antigen of standard formulations. A clinical trial of 31,989 participants published in the New England Journal of Medicine found it was 24.2% more effective than standard-dose vaccine in adults 65 and older (NEJM, 2014). The logic is straightforward: an aging immune system needs a louder signal to mount the same response.

RZV (Shingrix) works differently from the older live-attenuated zoster vaccine (Zostavax, now discontinued in the U.S.). Shingrix uses a recombinant glycoprotein antigen combined with AS01B adjuvant system — the adjuvant amplifies the immune response enough to achieve 91% efficacy against shingles in adults 70 and older, compared to roughly 38% efficacy for the discontinued live vaccine in the same age group (CDC, Shingrix Recommendations).

Pneumococcal vaccination involves navigating two distinct vaccine types: PCV20 (Prevnar 20) is a conjugate vaccine covering 20 pneumococcal serotypes; PPSV23 (Pneumovax 23) is a polysaccharide vaccine covering 23 serotypes. Conjugate vaccines generate a stronger, longer-lasting immune memory response — which is why the current preferred approach leads with PCV15 or PCV20 rather than PPSV23 alone.

Common scenarios

Adults who received PPSV23 before age 65 present the most common source of confusion. If PPSV23 was given before 65, a dose of PCV20 (or PCV15 followed by PPSV23) is still recommended at 65 or older, with a minimum interval of one year between the prior polysaccharide dose and the new conjugate dose.

Adults entering assisted living or nursing home care frequently arrive with incomplete or undocumented vaccination histories. Facilities regulated under CMS Conditions of Participation (42 CFR §483.80) are required to offer influenza and pneumococcal vaccines to all residents and document declinations. Coordination with incoming residents' primary care providers — ideally through the kind of care coordination that accompanies major care transitions — reduces duplication and catches gaps.

Adults managing immunosuppressive therapy for conditions like rheumatoid arthritis or post-transplant maintenance require individualized scheduling. Live vaccines are generally contraindicated during active immunosuppression. RZV (Shingrix) is a recombinant vaccine and thus can be used in many immunocompromised populations, though ACIP recommends it for adults 19 and older who are or will be immunodeficient — not just those 50 and older.

Caregivers and household contacts of older adults are also part of the equation. An unvaccinated family caregiver is a transmission vector. Family caregivers are specifically identified in ACIP guidance as a priority group for annual influenza vaccination.

Decision boundaries

Three questions help clarify when and whether a specific vaccine is appropriate for a given older adult.

Prior vaccination history: Pneumococcal and hepatitis B recommendations both hinge on what was received before 65 and when. The CDC's immunization history forms and state immunization information systems (IIS) are the first resources to consult — before assuming a vaccine is needed or already done.

Current immune status: An adult on high-dose corticosteroids (≥20 mg/day of prednisone or equivalent for ≥14 days, per ACIP thresholds) is managed differently than an immunocompetent adult of the same age. This is where medication management records become clinically relevant beyond just drug interactions.

Care setting timing: Hospitalizations, surgeries, and care transitions are often missed vaccination opportunities. Integrating vaccine review into advance care planning conversations and annual wellness visits closes that gap more reliably than reactive recall.

One structural reality worth acknowledging: Medicare Part B covers influenza, COVID-19, pneumococcal, and hepatitis B vaccines with no cost-sharing (Medicare.gov, Vaccine Coverage). Part D covers shingles vaccine. The coverage split between Part B and Part D is the single most common administrative friction point older adults encounter when trying to access vaccines they've already been told they need.